<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To determine how amyloid β 42 (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) levels in CSF behave in a large cohort of patients with different types of <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Baseline CSF was collected from 512 patients with <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> (AD) and 272 patients with other types of <z:hpo ids='HP_0000726'>dementia</z:hpo> (OD), 135 patients with a <z:e sem="disease" ids="C0004936" disease_type="Mental or Behavioral Dysfunction" abbrv="">psychiatric disorder</z:e> (PSY), and 275 patients with subjective memory complaints (SMC) </plain></SENT>
<SENT sid="2" pm="."><plain>Aβ42, t-tau, and p-tau (at amino acid 181) were measured in CSF by ELISA </plain></SENT>
<SENT sid="3" pm="."><plain>Autopsy was obtained in a subgroup of 17 patients </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: A correct classification of patients with AD (92%) and patients with OD (66%) was accomplished when CSF Aβ42 and p-tau were combined </plain></SENT>
<SENT sid="5" pm="."><plain>Patients with <z:e sem="disease" ids="C0038868" disease_type="Disease or Syndrome" abbrv="PSNP1">progressive supranuclear palsy</z:e> had <z:mpath ids='MPATH_458'>normal</z:mpath> CSF biomarker values in 90% </plain></SENT>
<SENT sid="6" pm="."><plain>Patients with <z:e sem="disease" ids="C0022336" disease_type="Disease or Syndrome" abbrv="">Creutzfeldt-Jakob disease</z:e> demonstrated an extremely high CSF t-tau at a relatively <z:mpath ids='MPATH_458'>normal</z:mpath> CSF p-tau </plain></SENT>
<SENT sid="7" pm="."><plain>CSF AD biomarker profile was seen in 47% of patients with <z:hpo ids='HP_0000726'>dementia</z:hpo> with <z:hpo ids='HP_0100315'>Lewy bodies</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e>), 38% in <z:e sem="disease" ids="C0393570" disease_type="Disease or Syndrome" abbrv="">corticobasal degeneration</z:e> (CBD), and almost 30% in <z:e sem="disease" ids="C0751072" disease_type="Mental or Behavioral Dysfunction" abbrv="FTLD">frontotemporal lobar degeneration</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FTLD</z:e>) and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VaD) </plain></SENT>
<SENT sid="8" pm="."><plain>PSY and SMC patients had <z:mpath ids='MPATH_458'>normal</z:mpath> CSF biomarkers in 91% and 88% </plain></SENT>
<SENT sid="9" pm="."><plain>Older patients are more likely to have a CSF AD profile </plain></SENT>
<SENT sid="10" pm="."><plain>Concordance between clinical and neuropathologic diagnosis was 85% </plain></SENT>
<SENT sid="11" pm="."><plain>CSF markers reflected neuropathology in 94% </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: CSF Aβ42, t-tau, and p-tau are useful in differential <z:hpo ids='HP_0000726'>dementia</z:hpo> diagnosis </plain></SENT>
<SENT sid="13" pm="."><plain>However, in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FTLD</z:e>, VaD, and CBD, a substantial group exhibit a CSF AD biomarker profile, which requires more autopsy confirmation in the future </plain></SENT>
</text></document>